- Coordinator
- Uniwersytet Jagiellonski, Poland
- Runs
- 1 April 2025 to 31 March 2030
- Status
- Running
- EU funding
- €1.7m
- Total cost
- —
- Partners
- 21 organisations in 10 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101179116
What the project is doing
In the project's own words, from its summary on CORDIS.
The MAP-ID project aims to deliver an East-West Europe-integrating training programme for PhD students, focused on tackling one of the most challenging, complex, and therapeutically unmet problems which are chronic inflammatory diseases. MAP-ID will train chronic inflammation-oriented researchers to become leaders in the field in regional, national, and international arenas. Within the doctoral programme, 13 DCs will conduct their research under the supervision of prominent specialists from the Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University in Poland (JU), in collaboration with international partner academic institutions and biotech companies.
MAP-ID focuses on multilevel approaches to understanding chronic inflammatory diseases, including infectious, autoimmune, allergic disorders, and cancer. To achieve this goal, the programme will establish and strengthen ties and collaborations between JU and top Universities and non-academic partners in Europe and beyond. MAP-ID aims to foster interdisciplinary research spanning molecular, cell, and structural biology, biophysics, chemistry, pharmaceutical sciences, and bioinformatics with a significant contribution of OMICS data sets.
The training will give the DCs a detailed insight into the strategies and mechanisms required to contribute to growth in the sector of academic and industrial research related to chronic inflammatory disease research and development. The training will include courses conducted by both host institution researchers and visiting scientists from world-leading Universities and companies. Some of the courses offered for DCs, created specifically for MAP-ID, will be accessible to other JU researchers, enriching the learning resources available to them.
Therefore, the MAP-ID will have a significant impact on the JU community and its public image, enabling JU to strengthen its position as a leader in chronic inflammation-related research in central Europe.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Uniwersytet Jagiellonski | Krakow | Poland | Coordinator |
| Medizinische Universitat Graz | Graz | Austria | Associatedpartner |
| Katholieke Universiteit Leuven | Leuven | Belgium | Associatedpartner |
| Universitat Zurich | Zurich | Switzerland | Associatedpartner |
| PerioTrap Pharmaceuticals GmbH | Halle | Germany | Associatedpartner |
| Fundacio Institut D'investigacio Biomedica De Bellvitge | L'Hospitalet De Llobregat | Spain | Associatedpartner |
| Fundacio Universitaria Balmes | Vic Barcelona | Spain | Associatedpartner |
| Universita Degli Studi Di Pavia | Pavia | Italy | Associatedpartner |
| Universita Degli Studi Di Roma La Sapienza | Roma | Italy | Associatedpartner |
| Academisch Ziekenhuis Groningen | Groningen | Netherlands | Associatedpartner |
| Bgi Tech Solutions (poland) Sp. Z O.o. | Warszawa | Poland | Associatedpartner |
| Bacteromic | Warsaw | Poland | Associatedpartner |
| Polski Bank Komorek Macierzystych S.a. | Warszawa | Poland | Associatedpartner |
| Ryvu Therapeutics S.A. | Kraków | Poland | Associatedpartner |
| Wpd Pharmaceuticals Spolka Z Ograniczona Odpowiedzialnoscia | Warszawa | Poland | Associatedpartner |
| intoDNA S.A. | Kraków | Poland | Associatedpartner |
| Cambridge Protein Works Limited | Cambridge | United Kingdom | Associatedpartner |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
| Board of Regents of Nevada System of Higher Education | Reno | United States | Associatedpartner |
| Virginia Commonwealth University | Richmond, VA | United States | Associatedpartner |
| West Virginia University | Morgantown | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI